Co-use of methylphenidate and selective serotonin reuptake inhibitors (SSRIs) for the treatment of attention-deficit/hyperactivity disorder (ADHD) and depression has a similar safety profile as methylphenidate monotherapy, according to study results published in JAMA Network Open.